AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, ...

The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena ...

AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

AbbVie has filed a lawsuit against BeiGene, alleging the biotechnology company of stealing trade secrets to develop a competing cancer therapy.

AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased at the upcoming European Society for Medical Oncology (ESMO) Congress ...

Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $218. Consistent in their evaluation, an analyst from Piper Sandler keeps a ...

The accelerated approval submission for Teliso-V will be reviewed under FDA's real-time oncology review program with an approval decision anticipated in 2025. AbbVie announced FDA breakthrough ...

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...